13-[2-Methoxy-4-(4-methylpiperazin-1-yl)anilino]-2,9-dimethyl-6-thia-2,9,12,14-tetrazatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-8-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 13-[2-Methoxy-4-(4-methylpiperazin-1-yl)anilino]-2,9-dimethyl-6-thia-2,9,12,14-tetrazatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-8-one
• 英文别名: 13-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-2,9-dimethyl-6-thia-2,9,12,14-tetrazatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-8-one
• 化学式: C₂₃H₂₇N₇O₂S
• 分子量: 465.579
• InChiKey: MBPLUEPXSUGGKX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  105
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS
  申请人：DANA-FARBER CANCER INSTITUTE, INC.

  公开号：US20160024115A1

  公开（公告）日：2016-01-28

  The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), LRKK2, EphA2, polo kinase 1,2,3, or 4, Ack1, Ack2, Abl, DCAMKL1, ABL1, Abl mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Abl, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC, and the use of such compounds in the treatment of various diseases, disorders or conditions.

  本发明涉及新型嘧啶二氮杂环庚内酮类化合物，调节蛋白激酶的方法，包括MPS1（TTK）、ERK5（BMK1，MAPK7）、LRKK2、EphA2、polo激酶1、2、3或4、Ack1、Ack2、Abl、DCAMKL1、ABL1、Abl突变体、DCAMKL2、ARK5、BRK、MKNK2、FGFR4、TNK1、PLK1、ULK2、PLK4、PRKD1、PRKD2、PRKD3、ROS1、RPS6KA6、TAOK1、TAOK3、TNK2、Bcr-Abl、GAK、cSrc、TPR-Met、Tie2、MET、FGFR3、Aurora、Axl、Bmx、BTK、c-kit、CHK2、Flt3、MST2、p70S6K、PDGFR、PKB、PKC、Raf、ROCK-H、Rsk1、SGK、TrkA、TrkB和TrkC等蛋白激酶的调节，以及这些化合物在治疗各种疾病、疾病或症状中的使用。
• PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF
  申请人：Anhui New Star Pharmaceutical Development Co., Ltd

  公开号：EP3424929A1

  公开（公告）日：2019-01-09

  The present invention relates to compounds (I) capable of inhibiting the Mstl/2 protein kinase activity, a preparation method therefor, a pharmaceutical composition comprising the compounds, and uses of the compounds and the pharmaceutical composition comprising the compounds in the preparation of drugs for prompting repair and regeneration of tissues and organs, prompting stem cell proliferation and somatic cell dedifferentiation, immunosuppression, and preventing or treating diseases related to nervous disorders and local ischemia.

  本发明涉及能够抑制Mstl/2蛋白激酶活性的化合物（I）、其制备方法、包含该化合物的药物组合物，以及该化合物和包含该化合物的药物组合物在制备药物中的用途，以促进组织和器官的修复和再生、促进干细胞增殖和体细胞去分化、免疫抑制，以及预防或治疗与神经紊乱和局部缺血有关的疾病。
• Pyrimido-diazepinone compounds and methods of treating disorders
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10189861B2

  公开（公告）日：2019-01-29

  The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), LRKK2, EphA2, polo kinase 1, 2, 3, or 4, Ack1, Ack2, Abl, DCAMKL1, ABL1, Abl mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Abl, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC, and the use of such compounds in the treatment of various diseases, disorders or conditions.

  本发明涉及新型嘧啶类二氮杂卓酮化合物、调节蛋白激酶的方法，包括MPS1（TTK）、ERK5（BMK1、MAPK7）、LRKK2、EphA2、polo 激酶 1、2、3 或 4、Ack1、Ack2、Abl、DCAMKL1、ABL1、Abl 突变体、DCAMKL2、ARK5、BRK、MKNK2、FGFR4、TNK1、PLK1、ULK2、PLK4、PRKD1、PRKD2、PRKD3、ROS1、RPS6KA6、TAOK1、TAOK3、TNK2、Bcr-Abl、GAK、cSrc、TPR-Met、Tie2、MET、FGFR3、Aurora、Axl、Bmx、BTK、c-kit、CHK2、Flt3、MST2、p70S6K、PDGFR、PKB、PKC、Raf、ROCK-H、Rsk1、SGK、TrkA、TrkB 和 TrkC，以及将这些化合物用于治疗各种疾病、失调或病症。
• Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof
  申请人：Anhui New Star Pharmaceutical Development Co., Ltd.

  公开号：US10975092B2

  公开（公告）日：2021-04-13

  The present invention relates to compounds (I) capable of inhibiting the Mst1/2 protein kinase activity, a preparation method therefor, a pharmaceutical composition comprising the compounds, and uses of the compounds and the pharmaceutical composition comprising the compounds in the preparation of drugs for prompting repair and regeneration of tissues and organs, prompting stem cell proliferation and somatic cell dedifferentiation, immunosuppression, and preventing or treating diseases related to nervous disorders and local ischemia.

  本发明涉及能够抑制 Mst1/2 蛋白激酶活性的化合物 (I)、其制备方法、包含该化合物的药物组合物，以及该化合物和包含该化合物的药物组合物在制备药物中的用途，以促进组织和器官的修复和再生、促进干细胞增殖和体细胞去分化、免疫抑制，以及预防或治疗与神经紊乱和局部缺血有关的疾病。
• PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE
  申请人：Li Xiaoxiang

  公开号：US20220280530A1

  公开（公告）日：2022-09-08

  The present invention provides a method of preventing or treating diseases and disorders associated with tissue damages using an MST1/2 protein kinase inhibitor. The MST1/2 protein kinase inhibitor may be administered in its prodrug or salt forms. A bioavailability enhancing agent or an absorption enhancing agent may be used in conjunction with the MST1/2 protein kinase inhibitor.